Citations 1
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Gojo, Ivana , Patnaik, Mrinal M. , Minden, Mark D. , Levonas, Amy, Fancourt, Craig, Meister, Amy, Kemp, Ramon K., Knox, Clayton D., Rose, Shelonitda, Patel, Payal Shah, Ravandi, Farhad , Kantarjian, Hagop M. , Lam, Raymond, Jones, Mary Elizabeth , Patel, Payal Shah, Tibes, Raoul
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7070-7070
